UnknownNot Applicable

Withdrawal or Reduction TKIs in CML-CP

China100 participantsStarted 2019-10-23

Plain-language summary

Compare MMR on 12 month treated with half TKIs(including imatinib, dasatinib, and nilotinib) or TKIs withdrawal.

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Age 18-70 years old, gender is not limited;
✓. Diagnosed CML chronic phase and effective TKI(including imatinib, dasatinib, and nilotinib) was continued for more than 5 years
✓. Q-PCR monitored BCR/ABLIS duration \< 0.0032% in the last 18 months
✓. Informed consent of the patient or his legal representative

✕. Patients had history of CML-AP or CML-BC
✕. CML patients with previous or current ABL kinase mutations
✕. CML Patients who have received allogeneic hematopoietic stem cell transplantation
✕. CML Patients who have received immunotherapy (except interferon, including car-t and other cellular immunotherapy)
✕. Woman who is pregnant or nursing

MMR(BCR/ABL IS<0.01) on 12 moth

Timeframe: 12 moth

NCT IDNCT04143087

SponsorNanfang Hospital, Southern Medical University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-10-31

xu na